Tags

Type your tag names separated by a space and hit enter

Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Anesthesiology. 2007 Feb; 106(2):283-8.A

Abstract

BACKGROUND

Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This study explored the dose-response relation of sugammadex given as a reversal agent at reappearance of the second muscle twitch after rocuronium- and vecuronium-induced block. A secondary objective was to investigate the safety of single doses of sugammadex.

METHODS

In this two-center, phase II, dose-finding study, 80 patients (age >or= 18 yr, American Society of Anesthesiologists physical status I or II, surgery >or= 60 min requiring muscle relaxation for intubation) were randomly assigned to receive rocuronium (0.60 mg/kg) or vecuronium (0.10 mg/kg). Sugammadex or placebo was administered at reappearance of the second muscle twitch. The primary efficacy endpoint was time from starting sugammadex administration until recovery of the train-of-four ratio to 0.9.

RESULTS

Compared with placebo, sugammadex produced dose-dependent decreases in mean time to recovery for all train-of-four ratios in the rocuronium and vecuronium groups. The mean time for recovery of the train-of-four ratio to 0.9 in the rocuronium group was 31.8 min after placebo compared with 3.7 and 1.1 min after 0.5 and 4.0 mg/kg sugammadex, respectively. The mean time for recovery of the train-of-four ratio to 0.9 in the vecuronium group was 48.8 min after placebo, compared with 2.5 and 1.4 min after 1.0 and 8.0 mg/kg sugammadex, respectively. Sugammadex was well tolerated.

CONCLUSION

Sugammadex rapidly reversed rocuronium- or vecuronium-induced neuromuscular block at reappearance of the second muscle twitch and was well tolerated. A dose-response relation was observed with sugammadex for reversal of both rocuronium- and vecuronium-induced neuromuscular block.

Authors+Show Affiliations

Department of Anesthesiology and Critical Care Medicine, Onze Lieve Vrouw Ziekenhuis, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17264722

Citation

Suy, Koen, et al. "Effective Reversal of Moderate Rocuronium- or Vecuronium-induced Neuromuscular Block With Sugammadex, a Selective Relaxant Binding Agent." Anesthesiology, vol. 106, no. 2, 2007, pp. 283-8.
Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106(2):283-8.
Suy, K., Morias, K., Cammu, G., Hans, P., van Duijnhoven, W. G., Heeringa, M., & Demeyer, I. (2007). Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology, 106(2), 283-8.
Suy K, et al. Effective Reversal of Moderate Rocuronium- or Vecuronium-induced Neuromuscular Block With Sugammadex, a Selective Relaxant Binding Agent. Anesthesiology. 2007;106(2):283-8. PubMed PMID: 17264722.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. AU - Suy,Koen, AU - Morias,Karl, AU - Cammu,Guy, AU - Hans,Pol, AU - van Duijnhoven,Wilbert G F, AU - Heeringa,Marten, AU - Demeyer,Ignace, PY - 2007/2/1/pubmed PY - 2007/3/14/medline PY - 2007/2/1/entrez SP - 283 EP - 8 JF - Anesthesiology JO - Anesthesiology VL - 106 IS - 2 N2 - BACKGROUND: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This study explored the dose-response relation of sugammadex given as a reversal agent at reappearance of the second muscle twitch after rocuronium- and vecuronium-induced block. A secondary objective was to investigate the safety of single doses of sugammadex. METHODS: In this two-center, phase II, dose-finding study, 80 patients (age >or= 18 yr, American Society of Anesthesiologists physical status I or II, surgery >or= 60 min requiring muscle relaxation for intubation) were randomly assigned to receive rocuronium (0.60 mg/kg) or vecuronium (0.10 mg/kg). Sugammadex or placebo was administered at reappearance of the second muscle twitch. The primary efficacy endpoint was time from starting sugammadex administration until recovery of the train-of-four ratio to 0.9. RESULTS: Compared with placebo, sugammadex produced dose-dependent decreases in mean time to recovery for all train-of-four ratios in the rocuronium and vecuronium groups. The mean time for recovery of the train-of-four ratio to 0.9 in the rocuronium group was 31.8 min after placebo compared with 3.7 and 1.1 min after 0.5 and 4.0 mg/kg sugammadex, respectively. The mean time for recovery of the train-of-four ratio to 0.9 in the vecuronium group was 48.8 min after placebo, compared with 2.5 and 1.4 min after 1.0 and 8.0 mg/kg sugammadex, respectively. Sugammadex was well tolerated. CONCLUSION: Sugammadex rapidly reversed rocuronium- or vecuronium-induced neuromuscular block at reappearance of the second muscle twitch and was well tolerated. A dose-response relation was observed with sugammadex for reversal of both rocuronium- and vecuronium-induced neuromuscular block. SN - 0003-3022 UR - https://www.unboundmedicine.com/medline/citation/17264722/Effective_reversal_of_moderate_rocuronium__or_vecuronium_induced_neuromuscular_block_with_sugammadex_a_selective_relaxant_binding_agent_ L2 - https://pubs.asahq.org/anesthesiology/article-lookup/doi/10.1097/00000542-200702000-00016 DB - PRIME DP - Unbound Medicine ER -